Neuropsychiatric systemic lupus erythematosus associated with neuroleptic malignant syndrome

A psychosis prevalence of 5% has been reported. 1,2 Neuroleptic malignant syndrome is a life-threatening complication of treatment with antipsychotics. 2 High-potency antipsychotics increase the risk. The introduction of droperidol led to a neuroleptic malignant syndrome with high creatinine phospho...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 2008-12, Vol.193 (6), p.507-508
Main Authors: Verdoot, Philippe, Constant, Eric L, Seghers, Arlette
Format: Article
Language:English
Subjects:
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotics
Blood pressure
C-reactive protein
Creatinine
Cytolysis
Delirium
Dibenzothiazepines - administration & dosage
Dibenzothiazepines - adverse effects
Droperidol - administration & dosage
Droperidol - adverse effects
Female
Fever
Humans
Hyperthermia
Life threatening
Lupus
Lupus erythematosus
Lupus Vasculitis, Central Nervous System - drug therapy
Malignant
Neuroleptic malignant syndrome
Neuroleptic Malignant Syndrome - etiology
Neurological complications
Psychiatry
Psychosis
Psychotropic drugs
Quetiapine Fumarate
Systemic lupus erythematosus
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A psychosis prevalence of 5% has been reported. 1,2 Neuroleptic malignant syndrome is a life-threatening complication of treatment with antipsychotics. 2 High-potency antipsychotics increase the risk. The introduction of droperidol led to a neuroleptic malignant syndrome with high creatinine phosphokinase levels, muscular rigidity, hyperthermia and blood pressure dysregulation. Biological features were abnormal with elevated creatinine phosphokinase (3415 UI/l), increased C-reactive protein (3.7 mg/dl) and hepatic cytolysis.
ISSN:0007-1250
1472-1465
DOI:10.1192/bjp.193.6.507a